Seres Therapeutics, Inc.
Seres Therapeutics, Inc. (MCRB) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Seres Therapeutics, Inc. (MCRB), featuring income statements, balance sheets, and cash flow data.
Seres Therapeutics, Inc. (MCRB) Income Statement & Financial Overview
Access detailed annual and quarterly income data for Seres Therapeutics, Inc. MCRB financial performance.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $1.42M |
| Gross Profit | $0.00 | $0.00 | $0.00 | -$1.42M |
| Gross Profit Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| R&D Expenses | $11.82M | $12.84M | $16.46M | $17.88M |
| SG&A Expenses | $11.89M | $12.46M | $12.71M | $16.06M |
| Operating Expenses | $27.24M | $28.84M | $29.17M | $32.51M |
| Total Costs & Expenses | $0.00 | $28.84M | $29.17M | $31.34M |
| Interest Income | $618000.00 | $437000.00 | $652000.00 | $1.23M |
| Interest Expense | $0.00 | $0.00 | $0.00 | $3.45M |
| Depreciation & Amortization | $0.00 | $3.09M | $1.40M | $1.42M |
| EBITDA | -$27.24M | -$12.54M | -$49.63M | -$28.003M |
| EBITDA Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | -$27.24M | -$28.84M | -$29.17M | -$31.34M |
| Operating Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Other Income/Expenses (Net) | $59.92M | $13.20M | -$21.86M | -$1.52M |
| Income Before Tax | $32.68M | -$15.64M | -$51.03M | -$32.87M |
| Income Before Tax Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $32.68M | -$15.64M | $88.78M | -$32.87M |
| Net Income Ratio | $0.00 | $0.00 | $0.00 | $0.00 |
| EPS | $3.76 | -$0.10 | $0.58 | -$0.22 |
| Diluted EPS | $3.75 | -$0.10 | $0.58 | -$0.22 |
| Weighted Avg Shares Outstanding | $8.70M | $7.70M | $7.63M | $7.58M |
| Weighted Avg Shares Outstanding (Diluted) | $8.71M | $7.70M | $7.63M | $7.58M |
The company's financials show resilient growth, with revenue advancing from $0.00 in Q2 2024 to $0.00 in Q1 2025. Gross profit remained healthy with margins at N/A in Q1 2025 compared to N/A in Q2 2024. Operating income hit -$27.24M last quarter, sustaining a consistent N/A margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$27.24M. Net income rose to $32.68M, while earnings per share reached $3.76. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan